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Background: Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the
human epidermal growth factor receptor 2 (HER 2) and inhibits carcinoma cellular proliferation. Its use as an
adjuvant for a period of one year is currently an internationally recognised standard for the treatment of localized
breast cancer. Its use is generally well tolerated, with the most salient side effect being a particular cardiotoxicity
that is typically manifested by an asymptomatic decrease in the left ventricular ejection fraction (LVEF) requiring
careful monitoring before and during treatment. To evaluate the cardiac safety of trastuzumab we conducted a
retrospective observational study of patients with HER2-positive localized breast cancer treated with trastuzumab
between May 2008 and May 2010 in Morocco.
Findings: The study comprised of 100 patients. The average in LVEF before the start of trastuzumab was 70%, and
at the end of treatment 66%, a decrease in absolute terms of 4%; this difference was statistically significant. 38% of
the patients exhibited cardiotoxicity. 97% of our patients have completed treatment, of whom 23% with a
provisional arrest because of a regressive fall in LVEF. A final arrest has been made in 3% of cases due to a non
regressive reduction in LVEF. A symptomatic heart failure was found in three patients. Analysis of risk factors toxicity
found a baseline LVEF higher in the patients who met cardiotoxicity than the rest of our sample.
Conclusions: The cardiac safety in our study seems comparable with the literature data but located in the upper
range of levels of toxicity. Cardiotoxicity is the major complication of Trastuzumab, of which LV dysfunction is the
most common. Most instances are transient, asymptomatic and reversible.Introduction
Breast cancer is the most common malignant disease
and among the most frequent causes of cancer mortality
in females worldwide [1,2]. Overexpression of human
epidermal growth factor receptor type 2 (HER2) occurs
in 20-25% of invasive breast cancers, which is associated
with a poor prognosis [3,4].
Trastuzumab is a humanized monoclonal antibody
that binds to the extracellular domain of HER2 receptor
and inhibits carcinoma cellular proliferation [5].
Trastuzumab therapy is important in the treatment of
early and advanced disease as shown in multiple ran-
domized trials. Its use as an adjuvant treatment for a* Correspondence: m_meryem_a@hotmail.com
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reproduction in any medium, provided the orperiod of 1 year is currently an international standard of
care in HER 2 over expressed localized breast cancer. It
is generally well tolerated, with a low incidence of
adverse effects [6] of which the most relevant is
cardiotoxicity that had not been anticipated on the basis
of the results of preclinical or early clinical studies. It is
typically manifested by an asymptomatic decrease in left
ventricular ejection fraction (LVEF) and less often by
clinical heart failure [7].
It requires careful monitoring of the LVEF before and
during treatment. Trastuzumab cardiotoxicity was origin-
ally described in women with metastatic breast cancer and
in several subsequent trials of adjuvant trastuzumab, about
80% of trials show cardiotoxicity [8]. However, the inci-
dence of cardiotoxicity amongst populations of women
treated outside of this clinical trial is not well known.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1756-0500/6/339The purpose of this study is to evaluate the cardiotoxicity
incidence rate associated with adjuvant trastuzumab treat-
ment in clinical practice in a sample Moroccan population,
by describing its characteristics, management and potential
associated risk factors.
Patients and methods
This is a retrospective observational institutional study
conducted at the Department of Clinical Oncology, in the
national institute of oncology of Rabat from May 2008 to
May 2010.
Eligibility criteria
Eligible patients had localized breast cancer verified histologi-
cally and HER2 positive status assessed by immunohistoche-
mistry (3+) or fluorescent in situ hybridization positivity;
adequate cardiac function with normal LVEF≥ 50% measured
on echocardiography and who received adjuvant Tarstuzumab.
Ineligibility criteria included a history of documented
congestive heart failure, coronary artery disease with pre-
vious Q-wave myocardial infarction, angina pectoris re-
quiring medication, uncontrolled hypertension, clinically
significant valvular disease and unstable arrhythmias.
The study respected the ethical rules for medical research
involving human subjects as stipulated by the World Medical
Association in the Declaration of Helsinki. The local ethical
committee of the national institute of oncology of Rabat also
approved this study; and patients gave their consent.
Cardiac monitoring included physical examination and
an assessment of LVEF by echocardiography: it was eval-
uated before Trastuzumab administration and every
12 weeks thereafter for the duration of therapy.
Cardiotoxicity was defined as a LVEF decrease below nor-
mal values (50%) or an absolute decrease of >10 points below
the baseline value or any symptoms or signs of heart failure.
The following cardiovascular risk factors were analysed:
age, overweight body mass index (BMI > 25 kg/m2 and
< 30 kg/m2), obesity (BMI ≥ 30 kg/m2), hypertension, dia-
betes, LVEF at baseline, number of anthracycline cycles.
Follow up
Patients were followed up until May, 2012. Any patients
who were not reviewed in the last consultation were
contacted again by telephone.
Statistical analysis
Data was analysed using an electronic CRF (case report
form).
The information was recorded in an Excel database
and analysed with the statistics software SPSS, version
12.0. A logistical regression analysis was performed to
examine which variables influenced whether or not a pa-
tient exhibited cardiotoxicity. A p value less than 0.05
was considered significant.Findings
A total of 100 patients were enrolled. The median age at
diagnosis was 46 years [range: 24-74]. According to
TNM staging, 11 patients had T1, 50 patients (50%) had
T2 and 39% had T3 or T4. 71 patients (71%) had posi-
tive lymph nodes. 67% of our patients were hormone re-
ceptor positive.
All patients received surgery, 22% had conservative
surgery and 78% received radical mastectomy with axil-
lary lymph nodes dissection. 40 patients (40%) received
chemotherapy based on anthracyclines and 60% had se-
quential chemotherapy with anthracyclines and taxanes.
93 patients had Radiotherapy, of whom 44 on the left
breast. All patients received adjuvant Trastuzumab. The
baseline characteristics of the patients and the Treatment
Delivered are detailed in Table 1. It must be stated that be-
fore starting the Trastuzumab treatment, 11% of the pa-
tients exhibited arterial hypertension and 7% diabetes.
Table 2 Characteristics of the LVEF decrease in patients with cardiotoxicity (n = 38)
Cardiotoxicity criteria No. patients % Patients with cardiotoxicity % of patient total
LVEF decrease <50% 7 18,42 7
LVEF decrease >10 points below baseline 16 42,10 16
LVEF decrease > 15 points below baseline 22 57,89 22
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http://www.biomedcentral.com/1756-0500/6/339The average in LVEF at baseline was 70% [55%-89%],
and it was 66% [42%-87%] at the end of treatment, a
decrease in absolute value by 4%. This difference was
statistically significant with p < 0, 0001.
38% of the patients presented cardiotoxicity according
to the predefined criteria; the details are listed in
Table 2.
Of the 38 patients who presented cardiotoxicity, 23
(60.52%) had to discontinue treatment; this number consti-
tutes 23% of the patient total. In 20 patients, treatment was
resumed after normalising parameters, the mediane recov-
ery time of LVEF was 21 days in both anthracycline alone
and sequential chemotherapy; 9 of these cases received
pharmacological treatment with angiotensin converting
enzyme inhibitors/angiotensin receptor antagonists.
Treatment was completed in 97% of our patients. De-
finitive Trastuzumab interruption was necessary in 3
patients due to the non-recovery of the ventricular func-
tion. A good clinical improvement was reached under
medical treatment. Three cases of grade 2 heart failure
(HF) according to the New York Heart Association
(NYHA) were noticed.
As shown in Table 3, when we analyse the influence of
each separate predictive factor for cardiac dysfunction
and the appearance of cardiotoxicity, we find no statisti-
cally significant differences for age, arterial hypertension,
diabetes, obesity, number of anthracycline cycles or





N = 100 N = 38
Age (years) 46 47
Overweight 38% 12 (31.57%)
obesity 35% 16 (42.10%)
Hypertension 11% 4 (10.52%)
Diabetes 7% 3 (7.89%)





Nb of anthracycline cycles 4 4
Concomitant radiotherapy with
trastuzumab
69 24 (63%)Patients who experienced toxicity have a slightly higher
mean age than those who did not, and relatively high
prevalence of obesity (42.1%); Paradoxically LVFE at the
baseline was significantly higher in the group of patients
who developed cardiac complications.Discussion
The resultant cardiotoxicity of the treatment in oncology
often limits its benefits [9]. This is why monitoring and
early prevention of aggressive anti-tumour treatment
cardiac complications is of clinical interest. Trastuzumab
is the standard drug for treating patients with breast
cancer that over express HER2 with the most adverse
effect being cardiotoxicity. It was initially described in
women with metastatic breast cancer, with a higher inci-
dence rate when trastuzumab was administered with
anthracyclines [10]. Based on this data, the concomitant
use of (anthracyclines and trastuzumab) was discouraged
due to the greater risk of causing cardiotoxicity.
Subsequently, several adjuvant clinical trials observed
cardiotoxicity, which was considered acceptable [8-11];
Cardiac function was carefully monitored, but difference
exists among the trials and how cardiotoxicity was de-
fined. In general these trials demonstrated that the risk
of symptomatic congestive heart failure was low; but
reveal a much greater asymptomatic decreases in left
ventricular ejection fraction [12].thout cardiac complications
cardiac
ons
Group with no cardiac
complications









25 (65.5%) Sequential 35 (56.5%) 0.3
e 13 (34.5%) anthracycline 27 (43.5%)
4 0.61
45 (72%) 0.318
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population of women receiving treatment outside of
clinical trials is unknown. The current study provides
insight into the common experience of trastuzumab use
in real life situations common in oncology and cardi-
ology clinics. In a retrospectively evaluated population of
100 HER2 positive, early and locally advanced breast
cancer women treated with trastuzumab in the adjuvant
setting, 38% of the patients exhibited cardiotoxicity and
nearly 23% required discontinuation of the medication
due to cardiac complications.
The incidence of left ventricular dysfunction in our
study (38%) is consistent with that reported in the com-
bined analysis of National surgical adjuvant breast and
bowel project (NSABP) B-31 (34%) [13], less than in
Breast Cancer International Research Group (BCIRG)
006 trial (18%) [14] and higher than in the HERceptin
Adjuvant (HERA) trial (7.1%) [15]. In our study, 23% of
patients had to suspend trastuzumab treatment, whether
temporarily or definitively, due to cardiotoxicity. In the
McArthur and Chia study [16] the rate of treatment sus-
pension due to cardiac dysfunction was 21.6% which is
higher than the number reported in the HERA clinical
trial [17] and closer to the rate shown by our patient’s
series. However, the same study shows that most of the
patients who discontinued treatment were able to restart
it after recovering their cardiac function; in our study 20
of the patients who interrupted treatment ended up
suspending it definitively.
Symptomatic heart failure events have been observed
much less frequently than asymptomatic LV dysfunction.
1.9% in BCIRG 006, 4% in NSABP B-31 and 0.6% in the
HERA trial of trastuzumab treated patients reported
severe symptoms of HF (NYHA III/IV) [13-15].
Tarantini et al. reported 3% symptomatic heart failure
incidence in a cohort of 499 women with HER2 positive
early breast cancer from 10 Italian institutions treated
with trastuzumab observed retrospectively [18]. Such in-
cidence is consistent with that in our study, in which 3%
of patients complained of mild heart failure symptoms.
The majority of complications are asymptomatic. The
asymptomatic nature of cardiac complications makes
monitoring of trastuzumab therapy safety mandatory. This
issue has been addressed and regulated by a few guidelines
[19,20]. They suggest that detection of heart damage due
to trastuzumab therapy is best accomplished via sequential
measurements of LVEF, either by multiple-gated acquisi-
tion scans (MUGA) or by echocardiography techniques.
In addition to imaging methods, the literature suggests
that measurement of plasma markers, such as brain natri-
uretic peptide (BNP) as a marker of LV stretch and cardiac
troponins as markers of myocardium disintegration, may
be used to predict and to detect cardiac dysfunction dur-
ing treatment with trastuzumab [21].We found no differences in prevalence of cardiovascular
risk factors between the group of patients with and with-
out cardiac complications; excepted LVEF at baseline, it
was paradoxically higher in the group of patients who de-
veloped cardiotoxicity. The association of cardiovascular
risk factors with trastuzumab related cardiotoxicity is not
apparent and not fully explained. The most well-known in-
dependent risk factors are advanced age and previous
exposure to anthracyclines [22]. In the NSABP B-31
and NCTTG N9831 trials age ≥ 50 years, requirement
for hypertension medications, previous exposure to
anthracyclines and LVEF at baseline < 55% were risk fac-
tors for heart failure in the course of trastuzumab treat-
ment in univariate analysis [23,24]. In the HERA trial
overweight and obesity were risk factors for cardiac to-
xicity but age, hypertension, dyslipidaemia and previous
heart disease did not increase the risk of trastuzumab-
related cardiotoxicity [15]. In a large retrospective co-
hort study the authors observed that anthracycline and
Trastuzumab were associated with increased HF [25].
The mechanisms of trastuzumab related cardiotoxicity re-
main uncertain. Genetic background has been suggested by
some studies [26,27]. There are two different hypothesis of
trastuzumab mechanism of cardiac damage in the literature.
Some preclinical data indicate that inhibition of the myocar-
dial HER2 receptor leads to changes in the tertiary structure
of the cardiac contractile apparatus, which seems likely to
be a reversible effect [28]. Others suggest that trastuzumab
induces apoptosis and cardiomyocytes’ death, which is likely
a progressive and rather irreversible condition [29]. Both
mechanisms may play a role in cardiotoxicity and numerous
external factors may decide which predominates and
whether heart damage is reversible.
The cardiotoxicity of trastuzumab is always reversible
(87% in our study) such as reported in others retrospec-
tives studies in adjuvant and metastatic setting [23,30].
The limitations of our study are its small sample size
and short follow-up. Despite these limitations, the results
we obtained coincide with published studies, in that
trastuzumab related cardiotoxicity in a clinical care setting
is more frequent than is shown by clinical trial estimates.
Conclusion
In conclusion, for trastuzumab, cardiotoxicity is its major
complication with LV dysfunction being the most com-
mon case. Most incidences are transient, asymptomatic
and reversible. Nevertheless, longer follow-up is needed
to confirm that cardiotoxicity associated with trastuzumab
therapy does not affect it’s long-term outcome. Prior to
the institution of trastuzumab therapy, all patients should
be evaluated for their cardiovascular status. As the majo-
rity of complications are asymptomatic, routine cardiac
monitoring must be performed during trastuzumab
treatment.
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